|
Gene: KRT5 |
Gene summary for KRT5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | KRT5 | Gene ID | 3852 |
Gene name | keratin 5 | |
Gene Alias | CK5 | |
Cytomap | 12q13.13 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | P13647 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3852 | KRT5 | GSM4909277 | Human | Breast | Precancer | 1.35e-03 | 5.99e-01 | 0.0177 |
3852 | KRT5 | GSM4909281 | Human | Breast | IDC | 5.75e-07 | 3.57e-01 | 0.21 |
3852 | KRT5 | GSM4909282 | Human | Breast | IDC | 1.35e-35 | 8.42e-01 | -0.0288 |
3852 | KRT5 | GSM4909285 | Human | Breast | IDC | 5.00e-87 | 1.37e+00 | 0.21 |
3852 | KRT5 | GSM4909290 | Human | Breast | IDC | 7.99e-05 | -2.33e-01 | 0.2096 |
3852 | KRT5 | GSM4909291 | Human | Breast | IDC | 1.66e-05 | -2.40e-01 | 0.1753 |
3852 | KRT5 | GSM4909293 | Human | Breast | IDC | 1.07e-03 | -1.96e-01 | 0.1581 |
3852 | KRT5 | GSM4909294 | Human | Breast | IDC | 3.42e-03 | -2.11e-01 | 0.2022 |
3852 | KRT5 | GSM4909295 | Human | Breast | IDC | 1.00e-11 | 7.14e-01 | 0.0898 |
3852 | KRT5 | GSM4909296 | Human | Breast | IDC | 1.47e-02 | -2.30e-01 | 0.1524 |
3852 | KRT5 | GSM4909297 | Human | Breast | IDC | 3.43e-03 | -1.95e-01 | 0.1517 |
3852 | KRT5 | GSM4909299 | Human | Breast | IDC | 1.21e-08 | 4.00e-01 | 0.035 |
3852 | KRT5 | GSM4909301 | Human | Breast | IDC | 3.84e-07 | -2.40e-01 | 0.1577 |
3852 | KRT5 | GSM4909302 | Human | Breast | IDC | 3.26e-05 | -2.05e-01 | 0.1545 |
3852 | KRT5 | GSM4909304 | Human | Breast | IDC | 8.25e-07 | -2.39e-01 | 0.1636 |
3852 | KRT5 | GSM4909305 | Human | Breast | IDC | 3.62e-03 | 4.01e-01 | 0.0436 |
3852 | KRT5 | GSM4909308 | Human | Breast | IDC | 3.63e-09 | -2.40e-01 | 0.158 |
3852 | KRT5 | GSM4909311 | Human | Breast | IDC | 6.92e-04 | 2.91e-03 | 0.1534 |
3852 | KRT5 | GSM4909312 | Human | Breast | IDC | 8.25e-07 | -2.40e-01 | 0.1552 |
3852 | KRT5 | GSM4909315 | Human | Breast | IDC | 1.79e-07 | -2.38e-01 | 0.21 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085445 | Breast | Precancer | epidermis development | 35/1080 | 324/18723 | 2.71e-04 | 3.96e-03 | 35 |
GO:000854412 | Breast | IDC | epidermis development | 41/1434 | 324/18723 | 1.03e-03 | 1.14e-02 | 41 |
GO:000854422 | Breast | DCIS | epidermis development | 40/1390 | 324/18723 | 1.05e-03 | 1.16e-02 | 40 |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:000854413 | Cervix | HSIL_HPV | epidermis development | 38/737 | 324/18723 | 1.92e-09 | 3.23e-07 | 38 |
GO:000854423 | Cervix | N_HPV | epidermis development | 21/534 | 324/18723 | 4.32e-04 | 6.01e-03 | 21 |
GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
GO:000854416 | Oral cavity | LP | epidermis development | 112/4623 | 324/18723 | 3.81e-05 | 5.61e-04 | 112 |
GO:000854424 | Oral cavity | EOLP | epidermis development | 64/2218 | 324/18723 | 2.48e-05 | 3.68e-04 | 64 |
GO:000854431 | Oral cavity | NEOLP | epidermis development | 57/2005 | 324/18723 | 1.13e-04 | 1.35e-03 | 57 |
GO:00085448 | Prostate | BPH | epidermis development | 80/3107 | 324/18723 | 1.12e-04 | 1.02e-03 | 80 |
GO:000854415 | Prostate | Tumor | epidermis development | 89/3246 | 324/18723 | 3.15e-06 | 5.18e-05 | 89 |
GO:000854417 | Skin | AK | epidermis development | 79/1910 | 324/18723 | 1.04e-13 | 3.25e-11 | 79 |
GO:000854418 | Skin | SCCIS | epidermis development | 40/919 | 324/18723 | 7.81e-08 | 1.15e-05 | 40 |
GO:000854425 | Skin | cSCC | epidermis development | 131/4864 | 324/18723 | 7.38e-09 | 2.39e-07 | 131 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KRT5 | insertion | Frame_Shift_Ins | novel | c.1353_1354dupTG | p.Glu452ValfsTer7 | p.E452Vfs*7 | P13647 | protein_coding | TCGA-P3-A5QA-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
KRT5 | insertion | Frame_Shift_Ins | novel | c.1475-1_1475insACTCAGTGGAGAAGGAGTTGGACCAGTCAACATCT | p.Ser492TyrfsTer63 | p.S492Yfs*63 | P13647 | protein_coding | TCGA-P3-A6SX-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | unknown | CR | ||
KRT5 | insertion | In_Frame_Ins | novel | c.725_726insTTTTTATCCATTTATTTTTTTAACCACAAA | p.Ser242_Glu243insPheTyrProPheIlePheLeuThrThrLys | p.S242_E243insFYPFIFLTTK | P13647 | protein_coding | TCGA-P3-A6SX-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | unknown | CR | ||
KRT5 | deletion | Frame_Shift_Del | novel | c.1153_1157delNNNNN | p.Glu385LeufsTer2 | p.E385Lfs*2 | P13647 | protein_coding | TCGA-TN-A7HJ-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR | ||
KRT5 | SNV | Missense_Mutation | c.647N>T | p.Glu216Val | p.E216V | P13647 | protein_coding | deleterious(0.02) | possibly_damaging(0.665) | TCGA-BR-8286-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
KRT5 | SNV | Missense_Mutation | c.649N>T | p.Pro217Ser | p.P217S | P13647 | protein_coding | deleterious(0.02) | possibly_damaging(0.733) | TCGA-BR-8361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
KRT5 | SNV | Missense_Mutation | rs776667863 | c.187C>T | p.Arg63Trp | p.R63W | P13647 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-CG-4306-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
KRT5 | SNV | Missense_Mutation | rs60271599 | c.1400N>C | p.Ile467Thr | p.I467T | P13647 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-CG-4436-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
KRT5 | SNV | Missense_Mutation | rs61297109 | c.991C>T | p.Arg331Cys | p.R331C | P13647 | protein_coding | deleterious(0.02) | possibly_damaging(0.89) | TCGA-SW-A7EA-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KRT5 | SNV | Missense_Mutation | rs374017172 | c.103N>A | p.Val35Met | p.V35M | P13647 | protein_coding | tolerated(0.07) | benign(0.051) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |